» Articles » PMID: 28742529

Risk Factors for Early Mortality on Antiretroviral Therapy in Advanced HIV-infected Adults

Abstract

Background: Many HIV-infected individuals present with advanced HIV disease. These patients are at high risk of death after antiretroviral therapy (ART) initiation, but risk factors for death in these patients are unclear.

Methods: We used data from a multisite randomized trial comparing empiric vs. preventive tuberculosis therapy in HIV-infected adults initiating ART with CD4 T-cell counts less than 50 cells/μl to evaluate risk factors for death within 48 weeks after ART initiation. Cox proportional hazards models were fit to evaluate characteristics present at baseline and at 4 weeks after ART initiation, including the week 4 CD4 T-cell response and new opportunistic infections.

Results: Of 850 enrolled, the median pre-ART CD4 T-cell count was 18 cells/μl and 67 (7.9%) died. Baseline risk factors for death included lymphadenopathy, lower CD4 T-cell count, lower serum albumin, high white blood cell count, elevated neutrophil percentage, and lower hemoglobin. Among 746 participants with data at week 4, the median changes in CD4 T-cell count and viral load for those who died (n = 43) vs. survived were 26 vs. 56 cells/μl and -2.7 vs. -2.7 log10 copies/ml, respectively. Each 20 cell/μl lower change in week 4 CD4 T-cell count was associated with a 20% increased risk of post week-4 mortality (adjusted hazard ratio 1.20, 1.01-1.42, P = .038).

Conclusion: Evidence of active infection and suboptimal immunologic response during the first month of ART are associated with death in the first year after ART initiation in those with advanced HIV disease taking tuberculosis preventive therapy. Strategies to reduce early mortality in this population warrant further investigation.

Citing Articles

Nutritional risk and HbA1c as critical risk factors and predictors of opportunistic infections in HIV-DM comorbid patients: a retrospective cross-sectional study.

Zhu Q, Gao F, Ren X, Li R, Kang J, Li M Front Endocrinol (Lausanne). 2025; 15:1527936.

PMID: 39866736 PMC: 11757115. DOI: 10.3389/fendo.2024.1527936.


Diagnosis and Management of Kaposi Sarcoma-Associated Herpesvirus Inflammatory Cytokine Syndrome in Resource-Constrained Settings: A Case Report and an Adapted Case Definition.

Kumwenda T, Hodson D, Rambiki K, Rambiki E, Fedoriw Y, Tymchuk C Trop Med Infect Dis. 2024; 9(12).

PMID: 39728834 PMC: 11680326. DOI: 10.3390/tropicalmed9120307.


Evaluation of Treatment Outcomes Among Individuals on Highly Active Antiretroviral Therapy in KwaZulu-Natal, South Africa.

Muzumbukilwa T, Manimani R, Mushebenge A, Vagiri R, Nlooto M AIDS Res Treat. 2024; 2024:8834740.

PMID: 39691492 PMC: 11651757. DOI: 10.1155/arat/8834740.


Do private providers initiate anti-tuberculosis therapy on the basis of chest radiographs? A standardised patient study in urban India.

Svadzian A, Daniels B, Sulis G, Das J, Daftary A, Kwan A Lancet Reg Health Southeast Asia. 2023; 13:100152.

PMID: 37383564 PMC: 10306035. DOI: 10.1016/j.lansea.2023.100152.


Effect of the relationship between anaemia and systemic inflammation on the risk of incident tuberculosis and death in people with advanced HIV: a sub-analysis of the REMEMBER trial.

Araujo-Pereira M, Krishnan S, Salgame P, Manabe Y, Hosseinipour M, Bisson G EClinicalMedicine. 2023; 60:102030.

PMID: 37287871 PMC: 10242630. DOI: 10.1016/j.eclinm.2023.102030.


References
1.
Johannessen A, Naman E, Ngowi B, Sandvik L, Matee M, Aglen H . Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis. 2008; 8:52. PMC: 2364629. DOI: 10.1186/1471-2334-8-52. View

2.
Lawn S, Edwards D, Kranzer K, Vogt M, Bekker L, Wood R . Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS. 2010; 23(14):1875-80. DOI: 10.1097/qad.0b013e32832e05c8. View

3.
Markowitz M, Nguyen B, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C . Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007; 46(2):125-33. DOI: 10.1097/QAI.0b013e318157131c. View

4.
Lederman M, Calabrese L, Funderburg N, Clagett B, Medvik K, Bonilla H . Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis. 2011; 204(8):1217-26. PMC: 3218674. DOI: 10.1093/infdis/jir507. View

5.
Hermans S, Kiragga A, Schaefer P, Kambugu A, Hoepelman A, Manabe Y . Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa. PLoS One. 2010; 5(5):e10527. PMC: 2866328. DOI: 10.1371/journal.pone.0010527. View